Hyperuricemia and chronic kidney disease: to treat or not to treat

• Autor(a) principal: Piani,Federica
• Data de Publicação: 2021
• Outros Autores: Sasai,Fumihiko, Bjornstad,Petter, Borghi,Claudio, Yoshimura,Ashio, Sanchez-Lozada,Laura G., Roncal-Jimenez,Carlos, Garcia,Gabriela E., Hernando,Ana Andres, Fuentes,Gabriel Cara, Rodriguez-Iturbe,Bernardo, Lanaspa,Miguel A, Johnson,Richard J
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Jornal Brasileiro de Nefrologia
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400572
• topic: Hyperuricemia; Uric Acid; Acute Kidney Injury; Renal Insufficiency, Chronic; Allopurinol; Cardiovascular Disease

Abstract Hyperuricemia is common in chronic kidney disease (CKD) and may be present in 50% of patients presenting for dialysis. Hyperuricemia can be secondary to impaired glomerular filtration rate (GFR) that occurs in CKD. However, hyperuricemia can also precede the development of kidney disease and predict incident CKD. Experimental studies of hyperuricemic models have found that both soluble and crystalline uric acid can cause significant kidney damage, characterized by ischemia, tubulointerstitial fibrosis, and inflammation. However, most Mendelian randomization studies failed to demonstrate a causal relationship between uric acid and CKD, and clinical trials have had variable results. Here we suggest potential explanations for the negative clinical and genetic findings, including the role of crystalline uric acid, intracellular uric acid, and xanthine oxidase activity in uric acid-mediated kidney injury. We propose future clinical trials as well as an algorithm for treatment of hyperuricemia in patients with CKD.